| 13.23 -0.15 (-1.12%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.35 | 1-year : | 16.99 |
| Resists | First : | 13.99 | Second : | 14.55 |
| Pivot price | 13.39  |
|||
| Supports | First : | 13.1 | Second : | 10.9 |
| MAs | MA(5) : | 13.27  |
MA(20) : | 13.48 |
| MA(100) : | 14.23 |
MA(250) : | 14.91 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 31.8 |
D(3) : | 28.3 |
| RSI | RSI(14): 34.8 |
|||
| 52-week | High : | 17.11 | Low : | 13.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TAK ] has closed above bottom band by 28.0%. Bollinger Bands are 13.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.34 - 13.41 | 13.41 - 13.45 |
| Low: | 13.05 - 13.14 | 13.14 - 13.2 |
| Close: | 13.1 - 13.24 | 13.24 - 13.32 |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Mon, 22 Apr 2024
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for ... - PR Newswire
Thu, 04 Apr 2024
Takeda Pharmaceutical Company Limited (NYSE:TAK) is XY Capital Ltd's 3rd Largest Position - MarketBeat
Sun, 03 Mar 2024
Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits (NYSE:TAK) - Seeking Alpha
Fri, 23 Feb 2024
A Decade Of Innovation: How This CEO Transformed A Global Pharma Giant - Forbes
Fri, 09 Feb 2024
Takeda Hits Accelerator On TAK-861 After Phase II Narcolepsy Win - Scrip
Fri, 09 Feb 2024
Takeda's TAK-861 shows promise in Phase IIb narcolepsy trial - Clinical Trials Arena
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 3,140 (M) |
| Held by Insiders | 1.55e+009 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 6,260 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4 |
| Profit Margin | 4.2 % |
| Operating Margin | 9.4 % |
| Return on Assets (ttm) | 2.6 % |
| Return on Equity (ttm) | 2.7 % |
| Qtrly Rev. Growth | 1.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 7.72 |
| EBITDA (p.s.) | 2.24 |
| Qtrly Earnings Growth | -12.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 731,450 (M) |
| PE Ratio | 36.74 |
| PEG Ratio | 0 |
| Price to Book value | 3.3 |
| Price to Sales | 1.71 |
| Price to Cash Flow | 0.02 |
| Dividend | 0 |
| Forward Dividend | 8.12e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|